Analytical Data
-
Gene name
SGCD
- Application
-
Alternative Names
SGCD;Delta-sarcoglycan
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q92629
-
Expression Region
57-289aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH RSHMKVMNFT IDGMGNLRIT EKGLKLEGDS EFLQPLYAKE IQSRPGNALY FKSARNVTVN ILNDQTKVLT QLITGPKAVE AYGKKFEVKT VSGKLLFSAD NNEVVVGAER LRVLGAEGTV FPKSIETPNV RADPFKELRL ESPTRSLVME APKGVEINAE AGNMEATCRT ELRLESKDGE IKLDAAKIRL PRLPHGSYTP TGTRQKVFEI CVCANGRLFL SQAGAGSTCQ INTSVCL
-
Molecular Weight
28 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of SGCD (Sarcoglycan Delta) and its recombinant protein has garnered significant attention due to its critical role in muscle function and associated genetic disorders. SGCD is part of the sarcoglycan complex, which is essential for maintaining the structural integrity of muscle fibers. Mutations in the SGCD gene can lead to various forms of muscular dystrophy, particularly Limb-Girdle Muscular Dystrophy type 2F (LGMD2F), which is characterized by progressive muscle weakness and degeneration. Understanding SGCD's biological function and its interaction with other components of the muscle cell membrane is vital for developing targeted therapies. Recombinant protein technology allows for the production of SGCD in sufficient quantities for in-depth functional studies, facilitating the exploration of its role in muscle pathology and the potential for gene therapy approaches. Investigating the structure and function of SGCD not only aids in elucidating the mechanisms underlying muscular dystrophies but also opens avenues for therapeutic interventions, such as protein replacement strategies and gene editing. Therefore, research on SGCD recombinant proteins is essential in advancing our understanding of muscle diseases and improving treatment options for affected individuals.
